Catalyst overview
Research summary
This catalyst tracks a Failed discontinued for CT-95 in Solid tumor/s. The expected timing is based on the latest available company guidance and may change.
4/9/25- First patient dosed. 11/7/25- Trial presented at SITC'25. Initial data by mid-2026. 11/05/25:- Ongoing Ph1 dose escalation has enrolled 6 patients with no DLTs or MTD reached. Initial Ph1a data remain expected in mid-2026 as escalation continues toward target exposure levels. 03/23/26:- Phase 1a interim CT-95 data webinar expected September 2026 as dose escalation continues. 05/06/26:- Phase 1a interim CT-95 data expected in September 2026 remains on track. 08/05/26:- CT-95 development was discontinued under portfolio prioritization.
Verification
Confirm timing and program details against the company announcement or filing.